Jeffrey T. Kirby - Concepedia

Author

Jeffrey T. Kirby

JMI Laboratories

Also Known As

J. Kirby, Jeffrey T Kirby, Jeffrey T. Kirby

Publications

820

Citations

H-Index

Concepts

All Affiliations

JMI Laboratories Tufts University University of Iowa

About

Jeffrey T. Kirby is an author at JMI Laboratories specializing in medicine, clinical microbiology, and infection control.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	446
2	Health Sciences	3	3	161
3	Public Health	2	2	95
4	Epidemiology	2	2	73
5	Health Management	1	1	59

Jeffrey T. Kirby

Publications

812

Citations

H-Index

Page 1

	Year	Citations
Antimicrobial Susceptibility and Epidemiology of a Worldwide Collection of <i>Chryseobacterium</i> spp.: Report from the SENTRY Antimicrobial Surveillance Program (1997-2001) Jeffrey T. Kirby, Hélio S. Sader, Timothy R. Walsh, Journal of Clinical Microbiology	2004	280
Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997–2000) Ronald N. Jones, Jeffrey T. Kirby, Mondell L. Beach, Diagnostic Microbiology and Infectious Disease Antimicrobial SusceptibilityHealth SciencesAntibioticsAntimicrobial StewardshipBroad-spectrum β-Lactams	2002	90
Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against <i>Candida</i> spp., <i>Cryptococcus</i> spp., and <i>Aspergillus</i> spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) S. A. Messer, Gary J. Moet, Jeffrey T. Kirby, Journal of Clinical Microbiology Fungal DiversityAntifungal AgentAntibioticsContemporary Antifungal AgentsAntifungal Agents	2009	75
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections Thomas R. Fritsche, Jeffrey T. Kirby, Ronald N. Jones Diagnostic Microbiology and Infectious Disease Gram-positive Cutaneous InfectionsMedicineRecent Clinical IsolatesInfection ControlDermatology	2004	75
Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance Ronald N. Jones, Jeffrey T. Kirby, Paul R. Rhomberg Diagnostic Microbiology and Infectious Disease Health AdministrationPrimary CareComparative ActivityHealth PolicyUs Medical Centers	2008	59
Initial results from a longitudinal international surveillance programme for anidulafungin (2003) S. A. Messer, Jeffrey T. Kirby, Hélio S. Sader, Journal of Antimicrobial Chemotherapy	2004	52
Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006) Paul R. Rhomberg, Lalitagauri M. Deshpande, Jeffrey T. Kirby, Diagnostic Microbiology and Infectious Disease Translational MedicineSerine CarbapenemasesPharmacologyUs Medical CentersMystic Program	2007	40
Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: Report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America) Jeffrey T. Kirby, Thomas R. Fritsche, Ronald N. Jones Diagnostic Microbiology and Infectious Disease OncologyHealth SciencesAntibioticsHematologyChemotherapy Alliance	2006	37
Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000) Jeffrey T. Kirby, Alan H. Mutnick, Ronald N. Jones, Diagnostic Microbiology and Infectious Disease Soft Tissue InfectionsAntibioticsHealthcare-associated InfectionClinical EpidemiologyClinical Infection	2002	36
CANCER Resistance Surveillance Program: Initial Results from Hematology–Oncology Centers in North America Alan H. Mutnick, Jeffrey T. Kirby, Ronald N. Jones Annals of Pharmacotherapy	2003	34

Page 1